A detailed study on Biosimilar market complied by primary and secondary research and validated by industry experts. If you are planning to understand the Biosimilar market in and out, then this is a must have report. You will also get free analyst support with this report.
Biosimilar market is one of the markets, where investors have shown great interest. As per the research the market is expected to grow with a CAGR of XX% in coming years. Biosimilar Market Sizes, Shares, Prices, Trends, and Forecasts have been derived from an in-depth study of the current scenarios in the. This report is based on both value and volume (Where applicable).
*This is a smart report which can be customized according to your need.
Highlights Of The Report:
1. Market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends.
3. Historical data and forecast.
4. Estimations for the forecast period between 2020 and 2026.
5. Developments and trends in the market.
6. By Type:
Human Growth Hormones
Monoclonal Antibodies
Insulin
Peptides
Erythropoietin
7. By Application:
Oncology
Chronic and Autoimmune Diseases
Growth Hormone Deficiency
Infectious Diseases
Others
8. Market scenario by region, sub-region, and country.
9. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
10. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
11. Government Policies, Macro & Micro economic factors are also included in the report.Overview of the regional outlook of the market:
- The report offers information about the regions in the market, which is further divided into sub-regions and countries.
- In addition to the market share of each country and sub-region, information regarding lucrative opportunities is included in this chapter of the report.
- Share and market growth rate of each region, country, and sub-region are mentions in this chapter of the report during the estimated time period.
Companies profiled in this report:
1) Allergan plc
2) BIOCAD
3) Biocon
4) BioXpress Therapeutics
5) Boehringer Ingelheim
6) Celltrion
7) Coherus BioSciences
8) Dr. Reddys Laboratories
9) Genor BioPharma
10) Intas Pharmaceuticals Limited
11) Novartis
12) Pfizer
13) Reliance Life Sciences45*Additional companies can be added in Biosimilar market report as a part of free customization. Feel free to get in touch with our research analyst.
This chapter of the report comprises various key companies operating in the global market. This helps the reader understand the competitive landscape, including the strategies adopted by the players to stay in the competitive market.
- Market Share
- Company Profile
- Business Information
- SWOT Analysis
- Strategies
Reasons To Purchase The Biosimilar Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
- Moreover, we provide data support, in the excel format, and 1-year free analyst support.
Frequently Asked Questions?
A biosimilar is a medicine that is similar to a traditional medicine, but it has been developed using different methods. This means that the medicines are not identical, but they are designed to work in the same way.
Some of the key players operating in the biosimilar market are Allergan plc, BIOCAD, Biocon, BioXpress Therapeutics, Boehringer Ingelheim, Celltrion, Coherus BioSciences, Dr. ReddyÂ’s Laboratories, Genor BioPharma.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Biosimilar Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Biosimilar Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Biosimilar Market - Supply Chain
4.5. Global Biosimilar Market Forecast
4.5.1. Biosimilar Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Biosimilar Market Size (000 Units) and Y-o-Y Growth
4.5.3. Biosimilar Market Absolute $ Opportunity
5. Global Biosimilar Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Biosimilar Market Size and Volume Forecast by Type
5.3.1. Human Growth Hormones
5.3.2. Monoclonal Antibodies
5.3.3. Insulin
5.3.4. Peptides
5.3.5. Erythropoietin
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Biosimilar Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Biosimilar Market Size and Volume Forecast by Application
6.3.1. Oncology
6.3.2. Chronic and Autoimmune Diseases
6.3.3. Growth Hormone Deficiency
6.3.4. Infectious Diseases
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Biosimilar Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Biosimilar Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Biosimilar Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Biosimilar Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Biosimilar Demand Share Forecast, 2019-2026
9. North America Biosimilar Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Biosimilar Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Biosimilar Market Size and Volume Forecast by Application
9.4.1. Oncology
9.4.2. Chronic and Autoimmune Diseases
9.4.3. Growth Hormone Deficiency
9.4.4. Infectious Diseases
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Biosimilar Market Size and Volume Forecast by Type
9.7.1. Human Growth Hormones
9.7.2. Monoclonal Antibodies
9.7.3. Insulin
9.7.4. Peptides
9.7.5. Erythropoietin
9.7.6. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Biosimilar Demand Share Forecast, 2019-2026
10. Latin America Biosimilar Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Biosimilar Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Biosimilar Market Size and Volume Forecast by Application
10.4.1. Oncology
10.4.2. Chronic and Autoimmune Diseases
10.4.3. Growth Hormone Deficiency
10.4.4. Infectious Diseases
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Biosimilar Market Size and Volume Forecast by Type
10.7.1. Human Growth Hormones
10.7.2. Monoclonal Antibodies
10.7.3. Insulin
10.7.4. Peptides
10.7.5. Erythropoietin
10.7.6. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Biosimilar Demand Share Forecast, 2019-2026
11. Europe Biosimilar Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Biosimilar Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Biosimilar Market Size and Volume Forecast by Application
11.4.1. Oncology
11.4.2. Chronic and Autoimmune Diseases
11.4.3. Growth Hormone Deficiency
11.4.4. Infectious Diseases
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Biosimilar Market Size and Volume Forecast by Type
11.7.1. Human Growth Hormones
11.7.2. Monoclonal Antibodies
11.7.3. Insulin
11.7.4. Peptides
11.7.5. Erythropoietin
11.7.6. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Biosimilar Demand Share, 2019-2026
12. Asia Pacific Biosimilar Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Biosimilar Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Biosimilar Market Size and Volume Forecast by Application
12.4.1. Oncology
12.4.2. Chronic and Autoimmune Diseases
12.4.3. Growth Hormone Deficiency
12.4.4. Infectious Diseases
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Biosimilar Market Size and Volume Forecast by Type
12.7.1. Human Growth Hormones
12.7.2. Monoclonal Antibodies
12.7.3. Insulin
12.7.4. Peptides
12.7.5. Erythropoietin
12.7.6. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Biosimilar Demand Share, 2019-2026
13. Middle East & Africa Biosimilar Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Biosimilar Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Biosimilar Market Size and Volume Forecast by Application
13.4.1. Oncology
13.4.2. Chronic and Autoimmune Diseases
13.4.3. Growth Hormone Deficiency
13.4.4. Infectious Diseases
13.4.5. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Biosimilar Market Size and Volume Forecast by Type
13.7.1. Human Growth Hormones
13.7.2. Monoclonal Antibodies
13.7.3. Insulin
13.7.4. Peptides
13.7.5. Erythropoietin
13.7.6. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Biosimilar Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Biosimilar Market: Market Share Analysis
14.2. Biosimilar Distributors and Customers
14.3. Biosimilar Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Allergan plc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. BIOCAD
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Biocon
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. BioXpress Therapeutics
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Boehringer Ingelheim
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Celltrion
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Coherus BioSciences
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Dr. Reddys Laboratories
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Genor BioPharma
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Intas Pharmaceuticals Limited
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Novartis
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Pfizer
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Reliance Life Sciences
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook